Aneta Schieferdecker

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Meletios Α. Dimopoulos, Francesca Gay, Fredrik Schjesvold et al. · The Lancet · 2018 · 236 citations · Full text

Medicine, Hematology, Pharmacotherapy +15

Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma

Friederike Braig, Minna Voigtlaender, Aneta Schieferdecker et al. · Oncotarget · 2016 · 73 citations · Full text

Medicine, Cancer Biology, Oncology +17

Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer

Friederike Braig, Manuela März, Aneta Schieferdecker et al. · Oncotarget · 2015 · 65 citations · Full text

Medicine, Oncology, Pharmacology +17

Comparison of three different serum-free light-chain assays—implications on diagnostic and therapeutic monitoring of multiple myeloma

Aneta Schieferdecker, Sebastian Hörber, Monika Ums et al. · Blood Cancer Journal · 2020 · 44 citations · Full text

Medicine, Hematology, Hematologic Oncology +14

Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL

Aneta Schieferdecker, Mareike Voigt, Kristoffer Riecken et al. · Oncotarget · 2014 · 33 citations · Full text

Life Sciences, Oncology, Pharmacology +15